In vivo, using the subcutaneous MB49 bladder cancer model, HSV5-15 virus expressing both the cytokine and TLR agonist ...

CF33-hNIS has gained FDA orphan drug designation for the treatment of cholangiocarcinoma and is currently being evaluated in ...

Replimune's cash runway supports its accelerated approval and phase 3 trial. See why I think REPL's current low stock price ...

In a captivating Genomic Press Interview published in the peer-reviewed journal Genomic Psychiatry, Professor Mayana Zatz of ...

Canaccord Genuity analyst John Newman has maintained their bullish stance on ONCY stock, giving a Buy rating yesterday. John Newman has given ...

The global cancer gene therapy market is set for significant expansion, with projections indicating a robust compound annual ...

Theriva Biologics ($TOVX) is making noise in the field of immuno-oncology, supported by a promising pipeline. The stock is up ...

BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors. BT-001 in combination with ...

ImmunityBio's stock has risen sharply this year. Read more on whether investors should look closely at shares or avoid the ...

Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatmentIn a patient with a heavily pretreated leiomyosarcoma, BT ...

BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients. Promising efficacy ...